Brought to you by 
Recordati pays TND80mm for majority of Tunisian drug company Opalia
11 Sep 2020
Executive Summary
To continue expanding into emerging markets, Italian firm Recordati Industria Chimica & Farmaceutica SPA has paid TND80mm ($48mm) to acquire 90% of closely held Opalia Pharma SA, the eighth-leading drug manufacturer in the Northern African country of Tunisia. Recordati holds a put and call option to buy the remaining 10%.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Recordati pays TND80mm for majority of Tunisian drug company Opalia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice